---
title: "SERPINA1 Z allele linked to sarcopenia and higher mortality in UK Biobank analysis"
id: "medrxiv-12-the-alpha-1-antitrypsin-z-allele-associates-with-sarcopenia-in-the-uk-biobank"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-the-alpha-1-antitrypsin-z-allele-associates-with-sarcopenia-in-the-uk-biobank"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.12.26362905v1?rss=1"
published_at: "2026-09-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# SERPINA1 Z allele linked to sarcopenia and higher mortality in UK Biobank analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-the-alpha-1-antitrypsin-z-allele-associates-with-sarcopenia-in-the-uk-biobank
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.12.26362905v1?rss=1)
- **Published At:** 2026-09-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A retrospective analysis of 487,207 UK Biobank participants with SERPINA1 genotyping assessed associations between the **SERPINA1 Z allele** and skeletal muscle measures. - The study tested relationships between AAT genotypes (including PI*MM, PI*MZ, PI*SZ, PI*ZZ) and muscle indices: fat free mass index (FFMI) and appendicular skeletal muscle index (ASMI), and a binary sarcopenia definition. - Multivariable linear and logistic regression models adjusted for age, sex, smoking status, genetic principal components, lung function (FEV1% predicted), and liver fibrosis risk (FIB-4). - Carriers of the Z allele (PI*MZ, PI*SZ, PI*ZZ) had significantly lower FFMI and ASMI and higher odds of sarcopenia compared with PI*MM individuals; associations remained after adjustment for lung and liver function. - A dose-dependent effect was observed, with **PI*ZZ** individuals showing the largest reductions in muscle mass and the highest odds of sarcopenia (adjusted OR for FFMI-defined sarcopenia 2.02, 95% CI 1.16–3.32). - Each additional Z allele was associated with increased mortality risk (adjusted OR 1.09, 95% CI 1.02–1.16); mediation analysis estimated sarcopenia explained a modest proportion (~2.6%) of this association. - Authors conclude that the **Alpha-1 antitrypsin (AAT) Z allele** is associated with reduced muscle mass and increased sarcopenia risk independent of lung and liver disease, expanding the phenotypic spectrum of AAT deficiency to include skeletal muscle as a potential target for intervention. - Study limitations and other methodological details (e.g., specific sarcopenia binary definition thresholds) were not reported in the abstract and would require consultation of full text or supplementary materials. - Data access note: underlying UK Biobank data are available to approved researchers via the UK Biobank Research Analysis Platform under application number 61825. - Multiple authors disclosed industry relationships and funding sources including NIH and the Alpha-1 Foundation; IRB approval was provided by the Cleveland Clinic.
## Clinical Analysis & Structured Key Points
The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank | medRxiv Skip to main content The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank View ORCID Profile Amy H Attaway , Karina Serban , Shovan Dutta , Umur Hatipoglu , Joe Zein , Peter Bazeley , Maria Kyriakidou , Jennifer E Dawson , Lisa Ruvuna , R Chad Wade , Vickram Tejwani , Jessica Bon , J Michael Wells , Victor Ortega , James K Stoller , Russell Bowler doi: https://doi.org/10.64898/2026.09.12.26362905 Amy H Attaway 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Amy H Attaway For correspondence: attawaa{at}ccf.org Karina Serban 2 University of Florida; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shovan Dutta 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Umur Hatipoglu 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joe Zein 3 Mayo Clinic Arizona; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Peter Bazeley 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Kyriakidou 3 Mayo Clinic Arizona; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jennifer E Dawson 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lisa Ruvuna 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site R Chad Wade 4 University of Alabama at Birmingham; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vickram Tejwani 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jessica Bon 5 Wake Forest University Find this author on Google Scholar Find this author on PubMed Search for this author on this site J Michael Wells 4 University of Alabama at Birmingham; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Victor Ortega 3 Mayo Clinic Arizona; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James K Stoller 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Russell Bowler 1 Cleveland Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background. Sarcopenia is common in chronic obstructive pulmonary disease (COPD) and contributes to adverse outcomes. Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause of COPD, but its impact on skeletal muscle remains to be determined. Methods. We performed a retrospective analysis of 487,207 participants in the UK Biobank with available SERPINA1 genotyping. Associations between AAT genotypes and measures of skeletal muscle mass were determined using multivariable linear and logistic regression models. Models adjusted for age, sex, smoking status, genetic principal components, lung function (FEV₁% predicted), and liver fibrosis risk (FIB-4). We determined that the Z-allele was associated with sarcopenia and mortality using regression models and mediation analysis. Results. Compared with PI*MM individuals, carriers of the Z allele (PI*MZ, PI*SZ, PI*ZZ) demonstrated significantly lower fat free mass index (FFMI) and appendicular skeletal muscle index (ASMI), as well as higher odds of sarcopenia by binary definition. Associations persisted after adjustment for lung and liver function. A dose-dependent relationship was observed, with the greatest reductions in muscle mass and highest sarcopenia associated with PI*ZZ individuals (adjusted OR for FFMI-defined sarcopenia 2.02, 95% CI 1.16-3.32). Each additional Z allele was associated with increased mortality risk (adjusted OR 1.09, 95% CI 1.02-1.16), with sarcopenia mediating a modest proportion (~2.6%) of this association. Conclusions. The SERPINA1 Z allele is associated with reduced muscle mass and increased risk for sarcopenia independent of lung and liver disease. Our findings expand the phenotypic spectrum of AATD-related diseases to include skeletal muscle as a modifiable target for intervention. Competing Interest Statement Amy Attaway reports financial support was provided by National Institutes of Health. Amy Attaway reports was provided by Alpha-1 Foundation. Amy Attaway reports a relationship with American Thoracic Society that includes: speaking and lecture fees. Umur Hatipoglu reports royalties from UpToDate, Wolters Kluwer Health for associate editor for COPD section. Royalties from Elsevier as a coeditor of the textbook Egans Fundamentals of Respiratory Care. Consulting agreement with Viz.ai San Francisco, CA. Advisory board Genetech. Advisory board CITI Pharma. Jessica Bon reports consulting for Sanofi/Regeneron, AstraZeneca, GSK, Pfizer, Merck, Genentech, Chiesi, and speaking for Sanofi, GSK. James Michael Wells reports receiving grants and contracts to conduct research from Verona Pharma, Merck, Sanofi, Beam Therapeutics, American Lung Association, Alpha-1 Foundation, Chest Foundation, the NIH, and the Department of Veterans Affairs; he reports personal compensation for consulting and advisory work from AstraZeneca, Takeda, Sanofi, CSL Behring, Amgen, Verona Pharma, and Beam Therapeutics. Vickram Tejwani reports grant support from the NIH, Alpha-1 Foundation, Takeda, 4D Medical, and Fisher and Paykel Healthcare to his Institution, and honoraria for consulting by AstraZeneca, Sanofi, and Regeneron. James Stoller reports pro bono (Board of Directors member) Alpha-1 Foundation; Board Chairman, AlphaDetect. Consultant: Grifols, Sanofi, Takeda, CSL Vyfor, GondolaBio, Beam. Data Monitoring and Safety Board: Takeda. Research (funding to Cleveland Clinic): Takeda, Alpha-1 Foundation. R.P. Bowler reports grant support from the NIH. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB of Cleveland Clinic gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Access to the underlying UK Biobank data is available to approved researchers through the UK Biobank Research Analysis Platform. This study was conducted under UK Biobank application number 61825. Funder Information Declared NIH Common Fund, https://ror.org/001d55x84 , K08 HL168348 Alpha-1 Foundation, https://ror.org/04t31bx63 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 14, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank Amy H Attaway , Karina Serban , Shovan Dutta , Umur Hatipoglu , Joe Zein , Peter Bazeley , Maria Kyriakidou , Jennifer E Dawson , Lisa Ruvuna , R Chad Wade , Vickram Tejwani , Jessica Bon , J Michael Wells , Victor Ortega , James K Stoller , Russell Bowler medRxiv 2026.09.12.26362905; doi: https://doi.org/10.64898/2026.09.12.26362905 Share This Article: Copy Citation Tools The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank Amy H Attaway , Karina Serban , Shovan Dutta , Umur Hatipoglu , Joe Zein , Peter Bazeley , Maria Kyriakidou , Jennifer E Dawson , Lisa Ruvuna , R Chad Wade , Vickram Tejwani , Jessica Bon , J Michael Wells , Victor Ortega , James K Stoller , Russell Bowler medRxiv 2026.09.12.26362905; doi: https://doi.org/10.64898/2026.09.12.26362905 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (901) Anesthesia (331) Cardiovascular Medicine (4809) Dentistry and Oral Medicine (479) Dermatology (414) Emergency Medicine (648) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1626) Epidemiology (15935) Forensic Medicine (32) Gastroenterology (1202) Genetic and Genomic Medicine (7043) Geriatric Medicine (733) Health Economics (1064) Health Informatics (5041) Health Policy (1433) Health Systems and Quality Improvement (1760) Hematology (584) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16287) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (154) Nephrology (722) Neurology (7270) Nursing (366) Nutrition (1081) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3606) Ophthalmology (1051) Orthopedics (397) Otolaryngology (454) Pain Medicine (470) Palliative Medicine (139) Pathology (707) Pediatrics (1797) Pharmacology and Therapeutics (737) Primary Care Research (766) Psychiatry and Clinical Psychology (5890) Public and Global Health (9748) Radiology and Imaging (2417) Rehabilitation Medicine and Physical Therapy (1450) Respiratory Medicine (1247) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (776) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Nasal transcriptomics identify five asthma endotypes including T2‑low profiles in Puerto Rican and](https://medichelpline.com/clinical-feed/medrxiv-18-nasal-transcriptomics-characterize-t-helper-t-2-low-asthma-endotypes-in-a-study.md)
- [Triglyceride-Glucose (TyG) Index and Mortality in Non-Diabetic Fibrotic Lung Disease on Antifibrot](https://medichelpline.com/clinical-feed/plos-one-1-association-between-triglyceride-glucose-index-and-all-cause-mortality-in-non.md)
- [Tozorakimab shows ~30% reduction in COPD exacerbations in Phase 3 trials](https://medichelpline.com/clinical-feed/stat-news-0-stat-astrazeneca-s-experimental-copd-treatment-posts-strong-results-in-late.md)
- [Pemafibrate as a senotherapeutic for COPD via TFEB-driven autophagy and mitophagy regulation](https://medichelpline.com/clinical-feed/medrxiv-4-senotherapeutic-role-of-pemafibrate-through-autophagy-mitophagy-regulation-in.md)
- [CMS expands ACCESS model to cover four more chronic conditions in 2027](https://medichelpline.com/clinical-feed/healthcare-dive-2-cms-to-add-more-chronic-conditions-to-access-model-in-2027.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.